Atopic Dermatitis Clinical Trials

A listing of Atopic Dermatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 100 clinical trials
Neuropsychologic Assessments of Dupilumab-Treated Adolescents With Moderate-to-Severe Atopic Dermatitis (NEURADAD)

Primary Objective: Part A To quantify deficits in cognitive functioning in adolescents with moderate-to-severe AD, using the Conners' Continuous Performance Test 3rd Edition (CPT-3) d' T-score To determine the entry criterion (CPT-3 d' score) for Part B Primary Objective: Part B To measure changes in cognitive functioning in adolescents with …

  • 20 Oct, 2022
  • 9 locations
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 (TRuE-CHE2): A Phase 3, Double-Blind, Randomized, 16-Week, Vehicle Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema (TRuE-CHE2)

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity

  • 23 Oct, 2022
  • 4 locations
An Investigator-initiated, Multi-center, Randomized, Double-blind, Placebo Controlled Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema (DUPINUM)

inhibiting the IL-4 and IL-13 pathway by targeting the IL-4-receptor, has been approved for the treatment of moderate-to-severe atopic dermatitis (AD). Since there is an overlap between AD and NE with both

  • 11 Oct, 2022
  • 1 location
A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group, Nutritional Intervention Study to Examine the Clinical and Immunological Effects of a Probiotic Food Supplement Containing B. Infantis (EVC001) in Healthy Breastfed Infants at Risk of Developing Atopic Dermatitis

The purpose of this study is to assess the effect of B. infantis (EVC001) versus placebo supplementation, in healthy breastfed infants at risk of developing atopic dermatitis (AD), on cumulative

Accepts healthy volunteers
  • 25 Oct, 2022
  • 1 location
GRANDIOSA - Growth, Allergy and Neurodevelopment in Infants on Hydrolysed Formula (GRANDIOSA)

originally been developed for treatment of cow's milk protein allergy. Certain hydrolysed formulae have been suggested to prevent atopic eczema when given to infants with a family history of allergic disease

Accepts healthy volunteers
  • 22 Oct, 2022
Clinic-Based Atopic Dermatitis Therapeutic Patient Education (AD-TPE)

) based on clinical outcomes than paper handouts in Spanish and English-speaking communities. The clinical outcomes being measured are the severity, sleep affected by atopic dermatitis (AD), and the

  • 07 Oct, 2022
  • 1 location
Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis (PAD)

treatment vs. vehicle treatment (active control comparator without crisaborole) in children with atopic dermatitis (AD). Participants, age 3 months to 5 years with symptomatic mild to moderate AD, along

crisaborole ointment
  • 04 Oct, 2022
  • 1 location
Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

Phase 2b study designed to evaluate the efficacy and safety of ASLAN004 in adult patients with moderate-to-severe Atopic Dermatitis (AD) who are candidates for systemic therapy. This study will

topical agents
topical corticosteroid
  • 07 Oct, 2022
  • 64 locations
Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis (MARBLE-23)

Mild-to-Moderate Atopic Dermatitis. It will consist of phase II and phase III parts, phase II will be a dose-ranging part and phase III will be a pivotal study part.

topical agents
  • 07 Oct, 2022
  • 18 locations
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin) (ADjoin)

This 110-week study is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis.

hormonal contraception
  • 28 Oct, 2022
  • 258 locations